We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 180

Oder of prohibition issues no promise to treatment in humans or reduced side effects was found
  • Borden Ladner Gervais LLP
  • Canada
  • April 30 2014

Pfizer’s Canadian Patent No. 2,177,576 for Celebrex has withstood Apotex’s allegations and was found to be valid; therefore the Minister is


Court of Appeal upholds decision awarding Section 8 compensation where sales related to “unauthorized indications” Sanofi-Aventis Canada Inc. v. Teva Canada limited, 2014 FCA 69
  • Borden Ladner Gervais LLP
  • Canada
  • March 24 2014

Drug: ramipril This was an appeal by Sanofi-Aventis Canada Inc. and Sanofi-Aventis Deutschland GmbH (collectively "Sanofi") from a judgment of the


Court of Appeal considers comity as it applies to NOC proceedings
  • Borden Ladner Gervais LLP
  • Canada
  • December 4 2012

Apotex v


Supreme Court denies Apotex leave to appeal; prohibition order stands
  • Borden Ladner Gervais LLP
  • Canada
  • April 30 2014

The Supreme Court of Canada (SCC) denied Apotex leave to Appeal the decision of the Federal Court of Appeal (FCA) in a s. 8 case (decision here


Generic association does not have standing to challenge listing on register of innovative drugs
  • Borden Ladner Gervais LLP
  • Canada
  • December 21 2010

The Canadian Generic Pharmaceutical Associate (CGPA) brought a judicial review application in respect of the listing of Avamys on the Register of Innovative Drugs (Register


Motion to strike judicial review application dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • January 5 2011

Apotex brought a judicial review application in respect of decisions made by the Minister of Health (the Minister) related to the review and approval of a submission relating to Apo-Omeprazole tablets


Costs awarded seven years after discontinuance
  • Borden Ladner Gervais LLP
  • Canada
  • December 21 2010

This decision relates to a motion brought by Bayer for an order for costs of an application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations


Pfizer v. Ratiopharm
  • Borden Ladner Gervais LLP
  • Canada
  • August 11 2010

The Court of Appeal dismissed Pfizer's appeal from a Trial Judge decision finding the patent at issue to be invalid


Court refuses to reconsider or vary its decision relating to redetermination
  • Borden Ladner Gervais LLP
  • Canada
  • December 7 2010

The Patented Medicines Prices Review Board (PMPRB) made a decision that Teva’s product COPAXONE had been sold at an excessive price


Pleadings amendments refused on the eve of trial
  • Borden Ladner Gervais LLP
  • Canada
  • February 7 2011

BMS brought a motion to strike out certain amendments made to its pleadings by Apotex